Filing Flows › Retractable Technologies (RVP) › Q2 2026 › vs Q1 2026
Retractable Technologies (RVP) Q2 2026 vs Q1 2026 (quarter over quarter)
Retractable Technologies's revenue rose $23K (+0.3%) from $7.2M in Q1 2026 to $7.2M in Q2 2026. The biggest changes: Syringes +$448K (+8%); EasyPoint Needles −$347K (-35%); Blood Collection Products −$79K (-21%).
Retractable Technologies, Q2 2026: revenue $7.2M (-31% year over year), operating margin -71.5%, net earnings $2.8M, operating cash flow −$1.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Syringes | $6.3M | $5.8M | $448K | +8% |
| EasyPoint Needles | $646K | $993K | −$347K | -35% |
| Blood Collection Products | $296K | $375K | −$79K | -21% |
| Other Products | $8K | $7K | $1K | +10% |
| Revenue | $7.2M | $7.2M | $23K | +0.3% |
| Other income, net | $8.0M | $1.9M | $6.0M | +310% |
| Costs & expenses | $15.2M | $13.3M | $1.8M | +14% |
| Operating costs | $12.3M | $13.3M | −$999K | -7% |
| Income tax | $2K | $2K | $0 | 0% |
| Net earnings | $2.8M | −$4.2M | $7.1M | — |
| Cost of revenue | $7.0M | $8.0M | −$1.0M | -13% |
| Research & development | $187K | $170K | $17K | +10% |
| Sales & marketing | $1.5M | $1.7M | −$199K | -11% |
| General & admin | $3.6M | $3.4M | $190K | +6% |
| Operating cash sources | $6.5M | −$952K | $7.4M | — |
| Depreciation & amortization | $1.9M | $1.9M | −$9K | -0.5% |
| Cash used in operations | $1.7M | $1.4M | $364K | +27% |
| Working capital & other | $6.5M | −$952K | $7.4M | — |
Questions
How much did Retractable Technologies's revenue grow quarter over quarter in Q2 2026?
Retractable Technologies's revenue rose $23K (+0.3%) from $7.2M in Q1 2026 to $7.2M in Q2 2026.
What drove Retractable Technologies's revenue change in Q2 2026?
Syringes +$448K (+8%); EasyPoint Needles −$347K (-35%); Blood Collection Products −$79K (-21%).